Healthcare / Medical Instruments & SuppliesShanghai
$16.98
-0.35 (-2.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-135.3M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-15.4%
↓Gross Margin
69.2%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+21.3%
FCF CAGR
—
FCF margin
-29.0%
FCF / Net income
0.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $278.8M · net income $-182.7M · FCF $-80.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $278.8M | $278.8M | $178.8M | $210.0M | $156.2M |
| Net Income | $-182.7M | $-182.7M | $-121.1M | $-156.4M | $-110.6M |
| EBITDA | $-97.7M | $-97.7M | $-51.0M | $-103.7M | $-95.7M |
| EPS | -0.40 | -0.40 | -0.27 | -0.35 | -0.26 |
| Gross Margin | 69.2% | 69.2% | 70.2% | 67.8% | 65.7% |
| Operating Margin | -51.6% | -51.6% | -73.4% | -94.2% | -93.7% |
| Net Margin | -65.5% | -65.5% | -67.7% | -74.5% | -70.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.16 | 0.18 | 0.09 |
| Current Ratio | 2.83 | 2.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-80.9M | $-80.9M | $-135.3M | $-391.5M | $-147.1M |
| Returns | |||||
| ROE | -15.4% | -15.4% | -9.6% | -12.6% | -10.6% |
| Valuation | |||||
| P/B | 6.54 | 6.54 | 3.21 | 4.57 | 4.98 |
| Growth & Yield | |||||
| Revenue Growth | 55.9% | 55.9% | -14.9% | 34.5% | — |
| EPS Growth | -48.1% | -48.1% | 22.9% | -34.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+36.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.27 → -0.40
Residual
+36.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.